Clinical utility of biochemical markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines

European Journal of Cancer

Volumn 39, Issue 6, 2003, Pages 718-727

  Duffy, M J ^a   Van Dalen, A ^b   Haglund, C ^c   Hansson, L ^d   Klapdor, R ^e   Lamerz, R ^f   Nilsson, O ^g   Sturgeon, C ^h   Topolcan, O ⁱ  

^a ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

^b Institute of Tumor Marker Oncology   (Netherlands)

^c HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^d UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^e Centre for Clinical and Experimental Tumour Diagnosis and Therapy   (Germany)

^f LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^g Fujirebio Diagnostics Inc   (Sweden)

^h ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

ⁱ CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Colorectal cancer, CEA; EGTM; Guidelines; Tumour markers

Indexed keywords

BIOCHEMICAL MARKER; CA 19-9 ANTIGEN; CA 242 ANTIGEN; CA 72-4 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE POLYPEPTIDE ANTIGEN; TUMOR MARKER;

ARTICLE; CANCER DIAGNOSIS; CANCER STAGING; CANCER SURGERY; COLORECTAL CANCER; DIAGNOSTIC ACCURACY; EARLY DIAGNOSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; EUROPE; HUMAN; INFORMATION; LIVER RESECTION; PATIENT MONITORING; PREOPERATIVE CARE; PRIORITY JOURNAL; PROGNOSIS; STANDARD;

EID: 0037375994     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(02)00811-0     Document Type: Article

References (71)

1. European Group on Tumor Markers. Anticancer Res. 19:1999;2785-2787.
2. Klapdor R., Aronsson A.-C., Duffy M.J.et al. Tumor markers in gastrointestinal cancers. EGTM recommendations Anticancer Res. 119:1999;2811-2815.
3. Hammarström S. The carcinoembryonic antigen (CEA) family. structure, suggested functions and expression in normal and malignant tissue Sem. Cancer Biol. 9:1999;67-81.
4. Duffy M.J. CEA as a marker for colorectal cancer. is it clinically useful Clin. Chem. 47:2001;624-630.
5. Parkin D.M., Pasini P., Ferlay J. Estimates of the worldwide incidence of 25 major cancers in 1999. Int. J. Cancer. 80:1999;827-841.
6. Burt R.W. Colon cancer screening. Gastroenterology. 119:2000;837-853.
7. Lewis J. Prevention and treatment of colorectal cancer. pay now or pay later Ann. Int. Med. 133:2000;647-649.
8. Thomson D.M.P., Krupey J., Freedman S.O., Gold P. The radioimmunoassay of circulating carcinoembryonic antigen of the human digestive system. Proc. Natl. Acad. Sci. USA. 64:1969;161-167.
9. Fletcher R.H. Carcinoembryonic antigen. Ann. Int. Med. 104:1986;66-73.
10. Carcinoembryonic antigen. its role as a marker in the management of cancer, Summary of an NIH consensus statement Lancet. 282:1981;373-375.
11. Clinical practice guidelines for the use of tumor markers in breast and colorectal cancer. J. Clin. Oncol. 14:1996;2843-2877.
12. McLeod H.L., Murray G.I. Tumor markers of prognosis in colorectal cancer. Br. J. Cancer. 79:1999;191-203.
13. Grem J. The prognostic importance of tumor markers in adenocarcinomas of the gastrointestinal tract. Curr. Opinion Oncol. 9:1997;380-387.
14. NIH Consensus Statement, Supplemental Information for NIH Consensus Statement on Adjuvant Therapy for Patients with Colorectal Cancer. http://odp.od.nih.gov/consensus/cons/079/079_supplement.htm.
15. Carriquiry L.A., Pineyro A. Should carcinoembryonic antigen be used in the management of patients with colorectal cancer? Dis. Colon Rectum. 42:1999;921-929.
16. Harrison L.E., Guillem J.G., Paty P., Cohen A.M. Preoperative carcinoembryonic antigen predicts outcome in node negative colon cancer patients. a multivariate analysis of 572 patients J. Am. Coll. Surg. 185:1997;55-59.
17. Compton C., Fenoglio-Preiser C.M., .Pettigrew N., Fielding L.P. American Joint Committee on Cancer Prognostic Factors Consensus Conference. Colorectal Working Group Cancer. 88:2000;1739-1757.
18. Compton C.C., Fielding L.P., Burgart L.J.et al. Prognostic factors in colorectal cancer. Arch. Pathol. Lab. Med. 124:2000;979-994.
19. Filella X., Molina R., Pique J.M.et al. CEA as a prognostic factor in colorectal cancer. Anticancer Res. 14:1994;705-708.
20. Berman J.M., Cheung R., Weinberg D.S. Surveillance after colorectal cancer resection. Lancet. 355:2000;395-399.
21. Pietra N., Sarli L., Costi R., Ouchemi C., Grattarola M., Peracchia A. Role of follow-up in management of local recurrence of colorectal cancer, a prospective randomized study. Dis. Colon Rectum. 41:1998;1127-1133.
22. Graham R.A., Wang S., Catalano P.J., Haller D.G. Post surgical surveillance of colon cancer. preliminary cost analysis of physician examination, CEA testing, chest X-ray and colonoscopy Ann. Surg. 228:1998;59-63.
23. Arnoud J.P., Koehl C., Adloff M. Carcinoembryonic antigen (CEA) in diagnosis and prognosis of colorectal carcinoma. Dis. Colon Rectum. 23:1980;141-144.
24. Moertel C.G., Fleming T.R., Macdonald J., Haller D.G., Laurie J.A., Tangen C. An evaluation of the carcinoembryonic antigen (CEA) test for monitoring patients with resected colon cancer. JAMA. 270:1993;943-947.
25. Hayes D., Bast R.C., Desch C.E.et al. Tumor marker utility grading system. a framework to evaluate clinical utility of tumor markers J. Natl. Cancer Instit. 88:1996;1456-1466.
26. Rosen M., Chan L., Beart R.W., Vukasin P., Anthone G. Follow-up of colorectal cancer. a meta analysis Dis. Colon Rectum. 41:1998;1116-1126.
27. Bruinvels D.J., Stiggelbout A.M., Kievit J., van Houwelingen H.C., Habbema D.F., van de Velde C.H. Follow-up of colorectal cancer. a meta-analysis Ann. Surg. 219:1994;174-182.
28. Renehan A.G., Egger M., Saunders M.P., O'Dwyer S.T. Impact on survival of intensive follow up after curative resection for colorectal cancer. systematic review and meta-analysis of randomised trials Br. Med. J. 324:2002;813-816.
29. Cromheecke M., de Jong K.P., Hoekstra H.J. Current treatment for colorectal cancer metastatic to the liver. Eur. J. Surgical Oncol. 25:1999;451-463.
30. Palliative chemotherapy for advanced colorectal cancer. systematic review and meta-analysis Br. Med. J. 321:2000;531-535.
31. Moertel C.G., Fleming T.R., Macdonald J.S., Haller D.G., Laurie J.A. Hepatic toxicity associated with fluorouracil plus levamisole adjuvant therapy. J. Clin. Oncol. 11:1993;2386-2390.
32. Quentmeier A., Schlag P., Hohenberger P., Schwarz V., Abel U. Assessment of serial carcinoembryonic antigen. determinations to monitor the therapeutic progress and prognosis of metastatic liver disease treated by regional chemotherapy J. Surg. Oncol. 40:1989;112-118.
33. Hohenberger P., Schlag P.M., Gernerth T., Herfath C. Pre and postoperative carcinoembryonic antigen determinations in hepatic resection for colorectal cancer metastases. Predictive value and implications for adjuvant treatment based on multivariate analysis. Ann. Surg. 219:1994;135-142.
34. Duffy M.J. CA 19-9 as a marker for gastrointestinal cancers. a review Ann. Clin. Biochem. 35:1998;364-370.
35. Lindmark G., Bergstrom R., Pahlman L., Glimelius B. The association of preoperative serum tumor markers with Dukes' stage and survival in colorectal cancer. Br. J. Cancer. 71:1995;1090-1094.
36. Nakayama T., Watababe M., Teramoto T., Kitajima M. CA 19-9 as a predictor of recurrence in patients with colorectal cancer. J. Surg. Oncol. 66:1997;238-243.
37. Reiter W., Stieber P., Reuter C.et al. Preoperative serum levels of CEA and CA 19-9 and their prognostic significance in colorectal carcinoma. Anticancer Res. 17:1997;2935-2938.
38. Reiter W., Stieber P., Reuter C.et al. Multivariate analysis of the prognostic value of CEA and CA 19-9 serum levels in colorectal cancer. Anticancer Res. 2000;5195-5198.
39. Behbehani A.I., Al-Sayer H., Farghaly M.et al. Prognostic significance of CEA and CA 19-9 in colorectal cancer in Kuwait. Int. J. Biol. Markers. 15:2000;51-55.
40. Filella X., Molina R., Piquet J.M.et al. Use of CA 19-9 in the early detection of recurrences in colorectal cancer. Comparison with CEA. Tumor Biol. 15:1994;1-6.
41. Hanke B., Riedel C., Lampert S.et al. CEA and CA 19-9 measurements as a monitoring parameter in metastatic colorectal cancer (CRC) under palliative first-line chemotherapy with weekly 24-hr infusion of high-dose 5-fluoruracil (5-FU) and folinic acid (FA). Ann. Oncol. 12:2001;221-226.
42. Carpelan-Holmstrom M., Haglund C., Lundin J.et al. Independent prognostic value of preoperative serum markers CA 242, specific tissue polypeptide antigen and human chorionic gonadtrophin beta, but not of carcinoembryonic antigen or tissue poypeptide antigen in colorectal cancer. Br. J. Cancer. 74:1996;925-929.
43. Carpelan-Holmstrom M., Haglund C., Lundin J.et al. Preoperative serum levels of CA 242 and CEA predict outcome in colorectal cancer. Eur. J. Cancer. 32A:1996;1156-1161.
44. Hall N.R., Finan P.J., Stephenson B.M., Purves D.A., Cooper E.H. The role of CA 242 and CEA in surveillance following curative resection for colorectal cancer. Br. J. Cancer. 70:1994;549-553.
45. Nilsson O., Johansson C., Glimelius B.et al. Sensitivity and specificity of CA 242 in gastrointestinal cancer. A comparison with CEA, CA 50 and CA 19-9. Br. J. Cancer. 65:1992;211-215.
46. Carpelan-Holmstrom M.A., Haglund C.H., Roberts P.J. Difference in serum tumor markers between colon and rectal cancer. Dis. Colon Rectum. 39:1996;799-805.
47. Hasholzner U., Stieber P., Reiter W., Zimmermann A., Hofmann K., Schalhorn A. CA 242 in comparison with established tumor markers in colorectal, pancreatic and lung cancer. Anticancer Res. 19:1999;2477-2480.
48. Carpelan-Holmstrom M.A., Haglund C.H., Jarvinen H.J.et al. Serum CA 242 and CEA detect different patients with recurrent colorectal cancer. Anticancer Res. 16:1996;981-986.
49. Von Kleist S., Hesse Y., Kananeeh H. Comparative evaluation of 4 tumor markers, CA 242, CA 19/9, TPA and CEA in carcinomas of the colon. Anticancer Res. 16:1996;2325-2331.
50. Chambers A.F., Matrisian L. Changing views of the role of matrix metalloproteinases in metastasis. J. Natl. Cancer Instit. 89:1997;1260-1270.
51. Holten-Andersen M.N., Christensen I.J., Nielsen H.J.et al. Total levels of tissue inhibitor of metalloproteinase 1 in plasma yield high diagnostic sensitivity and specificity in patients with colonic cancer. Clin. Cancer Res. 8:2002;156-164.
52. Holten-Andersen M.N., Stephens R.W., Nielsen H.J.et al. High preoperative plasma tissue inhibitor of metalloproteinase 1 are associated with short survival of patients with colorectal cancer. Clin. Cancer Res. 6:2000;4292-4299.
53. Fearon E.R., Vogelstein B. A genetic model for colorectal tumorigenesis. Cell. 61:1990;757-767.
54. Duffy M.J. Can molecular markers now be used for early diagnosis of malignancy? Clin. Chem. 41:1995;1410-1413.
55. Sidransky D., Tokino T., Hamilton S.R.et al. Identification of ras oncogene mutations in the stools of patients with curable colorectal tumors. Science. 256:1992;102-105.
56. Ahlquist D.A., Skoletsky J.E., Boynton K.A.et al. Colorectal cancer screening by detection of altered human DNA in stool. feasibility of a multitarget assay panel Gastroenterology. 119:2000;1219-1227.
57. Dong S.M., Traverso G., Johnson C.et al. Detecting colorectal cancer in stool with use of multiple genetic targets. J. Natl. Cancer Instit. 93:2001;858-865.
58. Ahlquist D.A., Shuber A.P. Stool screening for colorectal cancer. evolution from occult blood to molecular markers Clin. Chim. Acta. 315:2002;157-168.
59. Duffy M.J. Cellular oncogenes and suppressor genes as prognostic markers in cancer. Clin. Biochem. 26:1993;439-447.
60. McLeod H.L., Murray G.I. Tumor markers of prognosis in colorectal cancer. Br. J. Cancer. 72:1999;191-203.
61. Andreyev H.J., Norman A.R., Cunningham D.et al. Kirsten ras mutations in patients with colorectal cancer. the "RASCAL II" study Br. J. Cancer. 85:2001;692-696.
62. Shibata D., Reale M.A., Lavin P.et al. The DCC protein and prognosis in colorectal cancer. N. Engl. J. Med. 335:1996;1727-1732.
63. Gallinger S. Integration of molecular biology in diagnosis and treatment of colorectal cancer. American Society of Clinical Oncology Education Book. 2001;325-331.
64. Skelly M., Troy A., Duffy M.J.et al. Urokinase-type plasminogen activator in colorectal cancer. relationship with clinicopathological features and patient outcome Clin. Cancer Res. 3:1997;1837-1840.
65. Mulcahy H., Duffy M.J., Gibbons D.et al. Urokinase-type plasminogen activator and outcome in Dukes' B colorectal cancer. Lancet. 344:1994;583-584.
66. Duffy M.J., McCarthy K. Matrix metalloproteinases in cancer. prognostic markers and targets for therapy (Review) Int. J. Oncol. 12:1998;1343-1348.
67. Johnston P.G., Drake J.C., Trepel J., Allegra C.J. Immunological quantitation of thymidylate synthase using the monoclonal antibody TS 106 in 5 fluorouracil-sensitive and-resistant human cancer cell lines. Cancer Res. 52:1992;4306-4312.
68. Leichman C.G., Lenz H.-J., Leichman L.et al. Quantitation of intratumoral thymidylate synthase expression predicts for disseminated colorectal cancer response and resistance to protracted-infusion fluorouracil and weekly leucovorin. J. Clin. Oncol. 15:1997;3223-3229.
69. Catalano V., Baldelli A.M., Giordani P.et al. Molecular markers predictive of response to chemotherapy in gastrointestinal tumors. Crit. Rev. Oncol. Hematol. 38:2001;93-104.
70. Johnston P.G., Fisher E.R., Rockette H.E.et al. The role of thymidylate synthase expression in prognosis and outcome of adjuvant chemotherapy in patients with rectal cancer. J. Clin. Oncol. 12:1994;2640-2647.
71. Watanabe T., Wu T.-T., Catalano P.J.et al. Molecular predictors of survival after adjuvant chemotherapy for colon cancer. N. Engl. J. Med. 344:2001;1196-1206.